 IC50 = 2.297; IC50 = 4.693; IC50 = 2.011
INTRODUCTION
Esophageal adenocarcinoma is believed to be the most rapidly increasing cancer in Western countries. However, esophageal squamous cell carcinoma is the most common digestive system malignancy in Asia [1] . Although chemotherapy has been widely used in the clinical treatment of esophageal squamous cell carcinoma, unfortunately, the resistance to chemotherapy drugs, especially cisplatin chemoresistance, occurs in a large proportion of patients. [2, 3] . Therefore, exploring the molecular mechanisms responsible for the cisplatin chemoresistance of esophageal squamous cell carcinoma cells is of great significance to improve the therapeutic efficacy of cisplatin. The small non-coding regulatory RNAs, microRNAs (miRNAs) target numerous tissues and cells, including the nervous and immune systems. These molecules are involved in many biological and pathologic processes and function as oncogenes or tumor suppressors [4] . The miRNA-205 is a suppressor for many tumors such as breast cancer and prostate carcinoma [5] . However, the expression of miRNA-205 varies between tumors and remains controversial. Therefore, the expression of miRNA-205 and its downstream signaling pathway should be further studied in different cancers.
According to previous research, PTEN belongs to a family of inhibitory factors for tumors and can be regulated by miRNA-205 in many kinds of tumors. Moreover, the PI3K/AKT signaling pathway participates in the modulation of tumor development with miRNA-205 and PTEN [6] . In this study, the expression of miRNA-205 and PTEN in cisplatin-resistant esophageal squamous cell carcinoma cell lines was investigated. Furthermore, miRNA-205 was identified as a positive regulator of AKT signaling by targeting PTEN for downregulation.
EXPERIMENTAL

Establishment of cisplatin-resistant cell lines
TE13 cells were seeded in 6-well plates in Roswell Park Memorial Institute-1640 medium (RPMI-1640; Gibco, Grand Island, NY) and were treated with cisplatin at a concentration of 1.5 μg/mL every 24 h for 3 months. Before the experiment, the cis-TE13 cells were treated at a concentration of 1.5 ug/mL for three cycles, each lasting 72 h. Then, the cells were treated with cisplatin at a concentration of 2 μg/mL for three cycles, each lasting 72 h. Cisplatin-resistant cell lines were maintained in the continuous presence of 2 μg/mL cisplatin, which was supplemented every 72 h. The IC 50 values were used to evaluate the resistant cell model. The cells were grouped into two: TE13 (control) and cis-TE13 (cisplatin-resistant TE13 cells) [7] .
Overexpression and knockdown of miRNA-205 and PTEN in TE13 cells
The cis-TE13 cells were transfected with empty pCMV6 vector, pCMV6 with a sequence encoding for miRNA-205, empty pGEX-6p-1 vector, or pGEX-6p-1 with sequence encoding for PTEN (ORIGENE, Rockville, MD) using FuGENE HD (Roche, Shanghai, China). The oligonucleotide fragments of negative control (siNC-in) and siRNA targeting miRNA-205 (simiRNA-205) were purchased from Genephama Biotech (Shanghai, China) for the knockdown of miRNA-205 using FuGENE HD.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
Total RNA from TE13 and cis-TE13 cells was isolated using Trizol Reagent (Invitrogen). Then, the RNA was reverse transcribed into cDNA using SuperScript reverse transcriptase (ThermoFisher, Cheshire, UK). To test the transfection efficiency of miR-205 and PTEN, RT-PCR analysis was performed with primers for miR-205 and PTEN ( Table 1 ). The mRNA levels of miRNA-205 and PTEN were normalized with U6snRNA obtained with primers for U6 ( Table 1) .
Western blot assay
Whole cell lysates from TE13 cells following overexpression and knockdown of miRNA-205 and PTEN were extracted on ice with a solution containing Tris-HCl (20 mM, pH = 7.5), Triton X-100 (1 %), and PMSF (1 %). After protein quantitation, the proteins were separated by 10 % SDS-PAGE and were transferred on to PVDF membranes, which were blocked with 5% non-fat milk. Then the membranes were probed with antibodies against PTEN, AKT, p-AKT, or GAPDH (Abcam, Cambridge, MA) for 16 h at 4 ℃. Then, the membranes were incubated with secondary anti-goat and anti-mouse antibody for 2 h at 37 o C.
Luciferase reporter assay
The binding of miRNA-205 to PTEN 3'UTR was tested using a luciferase reporter assay. 
Flow cytometry assay
A Calibor TM cytometer (BD, American) was used to measure the DNA content and cell apoptosis with ModFit LT™ software. The TE13 cells were collected 45 h after transfection. Pancreatic enzymes with no EDTA were used for cell dissociation. Cells were washed with PBS and were resuspended in alcohol (70 %, 4 ℃) followed by the addition of PI/RNase staining buffer solution (Abcam) for incubation overnight at 4 ℃. After that, the solution was replaced with 500 μL PI/RNase staining buffer solution. In each sample, 20,000 events were analyzed.
Cellular viability assay
A total of 2 × 10 6 TE13 cells were seeded in 6-well plates in DMEM medium and grown in the normal environment. After 36 h, the cells were washed with PBS (Gibco), incubated with DAPI (Abcam) for 30 min, and then observed under a microscope.
CCK8 assay
A cell-counting kit (CCK8) assay was also conducted to test cell proliferation. Cells (1 × 10 5 ) were plated in 96-well plates and incubated with CCK-8 solutions (R&D Systems, Minneapolis, MN)) for 1.5 h at 37 °C.
Statistical analysis
All values are presented as mean ± standard deviation (SD) and were analyzed with GraphPad 7.0 and SPSS 18.0. Student's t-test was used to compare two groups, and one-way ANOVA and Dunnett test were used to compare several groups with the control. Two-tailed p values < 0.05 were considered statistically significant.
RESULTS
Aberrant expression of miRNA-205, PTEN, and PI3K/AKT signaling in cis-TE13 cells
Cisplatin-resistant cells were well-established as indicated by the difference in cell apoptosis between the TE13 cell line and the cis-TE13 cell line. The IC 50 value for the TE13 cell line was 0.304, while the value for cis-TE13 was 2.215 (Figure 1 A) . Results showed that the levels of miRNA-205 were increased in cis-TE13 cells (Figure 1 B) . The protein level of PTEN was decreased in cis-TE13 cells; however, the protein level of p-AKT was increased in cis-TE13 cells (Figure 1 C) . The protein level of AKT was not changed. 
Modulation of PTEN and PI3K/AKT signaling by miRNA-205 in cis-TE13 cells
Above results showed that cis-TE13 cells expressed higher level of miRNA-205 and lower level of PTEN than TE13 cells. Therefore, a luciferase reporter assay was performed to study the interaction between miRNA-205 and the PTEN gene. Figure 3A shows the sequence of PTEN 3'UTR and Mut and Wt miRNA-205 in the luciferase reporter assay. Figure 3B shows an increase in mRNA levels of miRNA-205 in cis-TE13 cells following miRNA-205 overexpression. Luciferase reporter assay results showed that the expression levels of fluorescent protein in the miRNA-205 overexpression group of PTEN 3'UTR-Wt cells were lower than that in the control group of PTEN 3'UTR-Wt. However, the expression levels of the fluorescent protein in the miRNA-205 overexpression group of PTEN 3'UTR-Mut was not changed when compared with the control group of PTEN 3'UTRWt ( Figure 3C ). These results indicate that PTEN is the target gene of miRNA-205. In addition, miRNA-205 overexpression decreased the protein level of PTEN, increased the protein level of p-AKT ( Figure 3D ), but did not change AKT protein levels ( Figure 3D ).
Improvement of resistance to cisplatin by overexpression of PTEN in cis-TE13 cells
In an effort to further confirm the effect of PTEN modulation in esophageal squamous cell carcinoma, PTEN was overexpressed in cis-TE13 cells, RT-qPCR result showed a successful overexpression of PTEN in cis-TE13 cells ( Figure  4A ). Following PTEN overexpression, the cis-TE13 cells were incubated with different concentrations of cisplatin. Compared with the control group, PTEN overexpression increased the sensitivity of cis-TE13 cells to cisplatin ( Figure 4B 
DISCUSSION
The current study demonstrated a carcinogenic and drug-resistance effect of miRNA-205. The first finding was aberrant expression of miRNA-205 and the downstream proteins PTEN and PI3K/AKT signaling pathway members in cisplatin resistant esophageal squamous cell carcinoma cells, consistent with a previous report [8] . It has been reported that the expression of miRNA-205 in esophageal squamous cell carcinoma clinical tissues was higher than in corresponding adjacent noncancerous tissue samples and that the expression was related to cancer stage, indicating that miRNA-205 is involved in the initiation and progression of esophageal squamous cell carcinoma [8] .
In this study, miRNA-205 knockdown in esophageal squamous cell carcinoma cells had anti-tumor effects, including decreased viability and increased cell apoptosis of cis-TE13 cells. Furthermore, miRNA-205 transcriptionally inhibits the expression of PTEN and consequently increases the expression of PI3K/AKT signaling pathway protein p-AKT. This result is consistent with results in lung cancer, in which PTEN is a target gene of miRNA-205 in A549 cells [9] . In addition, PTEN may act as an anti-tumor factor and directly decrease the expression of p-AKT. Moreover, co-transfection of miRNA-205 and PTEN demonstrated that PTEN may be an important node in the pathway involving miRNA-205 and p-AKT.
miRNA-205 influences many cancers as an inhibitory factor that functions via different signaling pathways. For example, miRNA exerts a suppressive role in human prostate cancer, as miRNA-205 plays a direct inhibitory role on the epithelial-to-mesenchymal transition through downregulation of the protein kinase C [10] . These results were first reported in 2009, and in 2014, the same laboratory reported that miRNA-205 influences the tumor microenvironment by preventing and reverting the oxidation in the process of the epithelial-to-mesenchymal transition [11] . Besides, miRNA-205 targets the E-cadherin transcriptional repressors ZEB1 and ZEB2 (also known as SIP1) to prevent the TGF-β-induced epithelial-to-mesenchymal transition [12] . Furthermore, the E2F1 transcription factor is another target protein, and miRNA-205 is reported to inhibit anti-cancer chemotherapy resistance through inhibition of the E2F1 transcription factor [13] . Accordingly, it is well known that miRNA-205 is an anti-tumor factor for many cancers. However, there are also some studies that discuss contrary findings that miRNA-205 has high expression in some kinds of cancers, such as laryngeal squamous cell carcinoma [14] . Strikingly, it is reported that miRNA-205 may be an esophageal squamous cell carcinoma-specific miRNA that exerts tumorsuppressive activities through regulation of zinc finger E-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells [15] .
A possible explanation for this inconsistency is that different cell lines were used. The gene expression profile of cisplatin-resistant cancer cells may be different from that of normal cancer cells [16] . Therefore, another normal control group was needed in the future study.
PTEN may also be the important anti-tumor factor in this cancer type. The cisplatin resistance-related effect of PTEN has been shown in previous studies in which PTEN inhibited the chemoresistance to cisplatin in epithelial ovarian cancer [17] . MiRNA-205-mediated PTEN downregulation is the key factor in chemoresistance of non-small cell lung cancer [18] . In non-small cell lung cancer, miRNA-205 was also reported to target PTEN and PHLPP2 for downregulation, thereby enhancing the proliferation of cancer cells [9] .
However, in this study, the expression of AKT was not changed in cis-TE13 cells and not influenced by miRNA-205 or PTEN overexpression in cisplatin-resistant cells, while p-AKT expression was increased by miRNA-205 overexpression and decreased by PTEN overexpression in cis-TE13 cells. Furthermore, the results in this study showed that p-AKT was a downstream factor of PTEN. In addition to PTEN/p-AKT signaling pathway, TGF-β signaling pathway also regulates miRNA-205 expression [19] , suggesting a possible interaction between different cell signaling pathways. 
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